A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial

By sjmartinez • June 22, 2024

McKetin R, Degan TJ, Saunders L, Nguyen L, Dore G, Shoptaw S, Farrell M, Degenhardt L, Kelly PJ, Turner A, Clare PJ, Dean OM, Arunogiri S, Colledge-Frisby S, Koeijers J, Goodman-Meza D, Sinclair B, Reid D, Hill H, Hayllar J, Christmass M, Cordaro F, Lundin R, Liaw W, Liu D, Holyoak E, Wu BT, Keygan J, Kontogiannis A, Palmer L, Morrison C, Wrobel A, Hyland B, Byrne M, Russell S, Zahra E, Berk M. A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial. Trials. 2024 Jun 22;25(1):408. doi: 10.1186/s13063-024-08238-y. PMID: 38907288; PMCID: PMC11193254.

Tags: Addiction, Clinical Trial, depression, Infectious Diseases, Methamphetamine, Mirtazapine, pharmacotherapy, Psychiatry, Publications, sleep, substance use disorders, Treatment

Operationalizing an adverse event detection surveillance system to support antimicrobial stewardship activities: perceptions and insights from the SHEA research network

Al Lawati HJ, Harvey KL, Shin M, Mull H, Lamkin RP, Golenbock S, Basnet-Thapa D, Strymish JM, Lee M, Gold H, Bidwell Goetz M, Branch-Elliman[...]

2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

Bhimraj A, Falck-Ytter Y, Kim AY, Li JZ, Baden LR, Johnson S, Shafer RW, Shoham S, Tebas P, Bedimo R, Cheng VC, Chew KW, Chiotos[...]

HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084

Fogel JM, Persaud D, Piwowar-Manning E, Richardson P, Szewczyk J, Marzinke MA, Wang Z, Guo X, McCauley M, Farrior J, Tran HV, Ungsedhapand C, Mathew[...]